DE19821060A1 - Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung - Google Patents

Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Info

Publication number
DE19821060A1
DE19821060A1 DE19821060A DE19821060A DE19821060A1 DE 19821060 A1 DE19821060 A1 DE 19821060A1 DE 19821060 A DE19821060 A DE 19821060A DE 19821060 A DE19821060 A DE 19821060A DE 19821060 A1 DE19821060 A1 DE 19821060A1
Authority
DE
Germany
Prior art keywords
cells
polypeptide
molecule
antibody
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19821060A
Other languages
German (de)
English (en)
Inventor
Richard Prof Dr Kroczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BUNDESREPUBLIK DEUTSCHLAND LET
Robert Koch Institute
Original Assignee
BUNDESREPUBLIK DEUTSCHLAND LET
Robert Koch Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7843330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19821060(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE19821060A priority Critical patent/DE19821060A1/de
Application filed by BUNDESREPUBLIK DEUTSCHLAND LET, Robert Koch Institute filed Critical BUNDESREPUBLIK DEUTSCHLAND LET
Priority to EP98956800A priority patent/EP1017723B1/de
Priority to AU13320/99A priority patent/AU752433B2/en
Priority to CA2305350A priority patent/CA2305350C/en
Priority to PCT/DE1998/002896 priority patent/WO1999015553A2/de
Priority to ES98956800T priority patent/ES2279585T3/es
Priority to US09/509,283 priority patent/US7259247B1/en
Priority to JP2000512857A priority patent/JP4463418B2/ja
Priority to DE59813875T priority patent/DE59813875D1/de
Publication of DE19821060A1 publication Critical patent/DE19821060A1/de
Priority to US09/823,307 priority patent/US7132099B2/en
Priority to US09/972,524 priority patent/US7125551B2/en
Priority to US10/647,072 priority patent/US7306800B2/en
Priority to US11/977,334 priority patent/US7722872B2/en
Priority to US11/977,342 priority patent/US20090074784A1/en
Priority to US11/977,335 priority patent/US20080118513A1/en
Priority to JP2009211970A priority patent/JP5021008B2/ja
Priority to US12/732,360 priority patent/US20120045447A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE19821060A 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung Withdrawn DE19821060A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
EP98956800A EP1017723B1 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
AU13320/99A AU752433B2 (en) 1997-09-23 1998-09-23 Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
CA2305350A CA2305350C (en) 1997-09-23 1998-09-23 Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
PCT/DE1998/002896 WO1999015553A2 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
ES98956800T ES2279585T3 (es) 1997-09-23 1998-09-23 Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso.
US09/509,283 US7259247B1 (en) 1997-09-23 1998-09-23 Anti-human T-cell costimulating polypeptide monoclonal antibodies
JP2000512857A JP4463418B2 (ja) 1997-09-23 1998-09-23 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
DE59813875T DE59813875D1 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
US09/823,307 US7132099B2 (en) 1997-09-23 2001-04-02 Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
US09/972,524 US7125551B2 (en) 1997-09-23 2001-10-04 Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide
US10/647,072 US7306800B2 (en) 1997-09-23 2003-08-22 Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
US11/977,334 US7722872B2 (en) 1997-09-23 2007-10-23 Treatment of cancer with antibodies to costimulating polypeptide of T cells
US11/977,342 US20090074784A1 (en) 1997-09-23 2007-10-23 Treatment of chronic viral diseases with antibodies to costimulating polypeptide of T cells
US11/977,335 US20080118513A1 (en) 1997-09-23 2007-10-23 Treatment of immune disorders with antibodies to costimulating polypeptide of T cells
JP2009211970A JP5021008B2 (ja) 1997-09-23 2009-09-14 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
US12/732,360 US20120045447A1 (en) 1997-09-23 2010-03-26 T cell costimulating polypeptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19741929 1997-09-23
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Publications (1)

Publication Number Publication Date
DE19821060A1 true DE19821060A1 (de) 1999-04-15

Family

ID=7843330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19821060A Withdrawn DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Country Status (3)

Country Link
US (6) US7132099B2 (cg-RX-API-DMAC7.html)
JP (1) JP5021008B2 (cg-RX-API-DMAC7.html)
DE (1) DE19821060A1 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936035A1 (de) * 1999-07-30 2001-02-08 Univ Leipzig Lymphozytenproliferationstestkit
US6803039B2 (en) * 2000-05-18 2004-10-12 Japan Tobacco Inc. Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en) 1997-02-27 2006-05-16 Japan Tobacco, Inc. Nucleic acids encoding JTT-1 protein
US7438905B2 (en) 2001-03-01 2008-10-21 Japan Tobacco, Inc. Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465444B2 (en) 2001-03-27 2008-12-16 Japan Tobacco, Inc. Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
US7465445B2 (en) 1999-08-30 2008-12-16 Japan Tobacco Inc. Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4463418B2 (ja) * 1997-09-23 2010-05-19 ドイツ連邦共和国 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP2332976B1 (en) * 1999-02-03 2014-04-02 Amgen, Inc Novel polypeptides involved in immune response
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US20050164260A1 (en) * 2003-12-30 2005-07-28 Sigma-Aldrich Co. Rapid preparation of nucleic acids by enzymatic digestion
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
CA2791975C (en) 2010-02-04 2021-02-09 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
KR102023661B1 (ko) * 2011-03-31 2019-09-23 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
UA129038C2 (uk) 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
KR900702370A (ko) 1988-10-06 1990-12-06 제임스 디. 그랜트 가용성 t세포 표면분자를 사용하는 치료 및 진단방법
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4463418B2 (ja) 1997-09-23 2010-05-19 ドイツ連邦共和国 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
EP2332976B1 (en) * 1999-02-03 2014-04-02 Amgen, Inc Novel polypeptides involved in immune response
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247612B2 (en) 1997-02-27 2007-07-24 Japan Tobacco Inc. Methods of treating an inflammatory disease with a JJT-1 polypeptide
US7196175B2 (en) 1997-02-27 2007-03-27 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US8389690B2 (en) 1997-02-27 2013-03-05 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en) 1997-02-27 2006-05-16 Japan Tobacco, Inc. Nucleic acids encoding JTT-1 protein
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US7932358B2 (en) 1997-02-27 2011-04-26 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7294473B2 (en) 1997-02-27 2007-11-13 Japan Tobacco Inc. Methods of identifying substances that interact with JTT-1 protein
US7217792B2 (en) 1997-02-27 2007-05-15 Japan Tobacco Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US7279560B2 (en) 1997-02-27 2007-10-09 Japan Tobacco Inc. Antibody fragments to JTT-1 protein and cells secreting such antibody fragments
US7226909B2 (en) 1997-02-27 2007-06-05 Japan Tobacco Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7259147B2 (en) 1997-02-27 2007-08-21 Japan Tobacco Inc. Methods of treating multiple sclerosis with a JTT-1 polypeptide
DE19936035C2 (de) * 1999-07-30 2002-11-21 Univ Leipzig Lymphozytenproliferationstestkit
DE19936035A1 (de) * 1999-07-30 2001-02-08 Univ Leipzig Lymphozytenproliferationstestkit
US7465445B2 (en) 1999-08-30 2008-12-16 Japan Tobacco Inc. Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
US7998478B2 (en) 1999-08-30 2011-08-16 Japan Tobacco, Inc. Pharmaceutical composition for treating immune diseases
US7166283B2 (en) 2000-05-18 2007-01-23 Japan Tobacco Inc. Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM
US7988965B2 (en) 2000-05-18 2011-08-02 Japan Tobacco, Inc. Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim
US6803039B2 (en) * 2000-05-18 2004-10-12 Japan Tobacco Inc. Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7438905B2 (en) 2001-03-01 2008-10-21 Japan Tobacco, Inc. Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465444B2 (en) 2001-03-27 2008-12-16 Japan Tobacco, Inc. Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
US8052972B2 (en) 2001-03-27 2011-11-08 Japan Tobacco, Inc. Remedies for inflammatory bowel diseases

Also Published As

Publication number Publication date
US20050261489A1 (en) 2005-11-24
US20090074784A1 (en) 2009-03-19
US20020182667A1 (en) 2002-12-05
US7132099B2 (en) 2006-11-07
JP2010042007A (ja) 2010-02-25
US7125551B2 (en) 2006-10-24
US20020177191A1 (en) 2002-11-28
JP5021008B2 (ja) 2012-09-05
US7306800B2 (en) 2007-12-11
US20080286283A1 (en) 2008-11-20
US7722872B2 (en) 2010-05-25
US20120045447A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
EP1017723B1 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
US7722872B2 (en) Treatment of cancer with antibodies to costimulating polypeptide of T cells
DE69333591T2 (de) CD40CR-Rezeptor und Liganden dafür
DE69535375T2 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE69132306T2 (de) Menschlicher und Murin-Interleukin-5-Rezeptor
DE68928915T2 (de) Immunotherapie mit einbeziehung der cd28-stimulation
DE60217839T2 (de) Mittel zur suppression von transplantat-abstossung
DE69233482T2 (de) Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69031410T2 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
DE69333038T2 (de) Chimäre rezeptorgene und entsprechend damit transformierte zellen
DE69000338T2 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
DE69738138T2 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
DE69320336T2 (de) Isolierung, Charakterisierung und Verwendung der menschlichen Beta-Einheit des Immunglobulin E-Hochaffinitätsrezeptors
EP1600460A1 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
DE69820449T2 (de) T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
DE69734141T2 (de) PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
DE69736109T2 (de) Differenzierungsinhibitor
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
DE69028713T3 (de) Schimäre immunoglobuline für cd4-rezeptoren
DE69931776T2 (de) Verfahren zur klonierung von genen
DE69623746T2 (de) Icam-4 material und verfahren
DE69434731T2 (de) Ein Gen das für ein Polypeptid kodiert welches die Fähigkeit hat Prä-B Zellwachstum zu ermöglichen
DE69825976T2 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
DE69929876T2 (de) Für hm1.24 antigen kodierendes gen und dessen promotor
DE69813181T2 (de) Icam-4 und dessen diagnostische verwendungen

Legal Events

Date Code Title Description
8141 Disposal/no request for examination